GSK gets US green light for two-drug HIV treatment
Pfizer Inc.
$25.33
06:40 18/04/24
-0.35%
-$0.09
GlaxoSmithkline said its two drug HIV treatment had been granted US market approval.
Dow Jones I.A.
37,998.40
04:30 15/10/20
n/a
n/a
FTSE 100
7,877.05
16:39 18/04/24
n/a
n/a
FTSE 350
4,336.44
16:30 18/04/24
n/a
n/a
FTSE All-Share
4,292.37
16:34 18/04/24
n/a
n/a
GSK
1,583.50p
16:40 18/04/24
-0.41%
-6.50p
Pharmaceuticals & Biotechnology
21,140.48
16:29 18/04/24
0.27%
56.47
The pharmaceutical company said on Tuesday the US Food and Drug Administration (FDA) had approved Dovato, a combination of dolutegravir and lamivudine, for the treatment of adults with no antiretroviral treatment history.
The drug is made by GSK's HIV drugs unit ViiV Healthcare, in which Pfizer and Shionogi also have a stake.
Viiv chief executive Deborah Waterhouse said Dovato would help patients “treat their HIV-1 infection with as few drugs as possible, marking a significant step in HIV treatment".